抗血管生成药物联合化疗治疗晚期非小细胞肺癌。
Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.
机构信息
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University Hospital, Baltimore, Maryland, USA.
出版信息
Cancer Invest. 2011 May;29(4):325-37. doi: 10.3109/07357907.2011.554476.
Abstract
Most patients with non-small cell lung cancer (NSCLC) present with advanced disease requiring systemic chemotherapy. Treatment with the antiangiogenic agent bevacizumab in combination with standard platinum-based doublet chemotherapy has been shown to improve outcomes in patients with advanced NSCLC. Several multitargeted antiangiogenic tyrosine kinase inhibitors (e.g., sorafenib, sunitinib, cediranib, vandetanib, BIBF 1120, pazopanib, and axitinib) are also being evaluated in combination with standard chemotherapy. Here we review current clinical data with combination therapy involving antiangiogenic agents and cytotoxic chemotherapy in patients with advanced NSCLC.
摘要
大多数非小细胞肺癌（NSCLC）患者为晚期疾病，需要进行全身化疗。抗血管生成药物贝伐珠单抗联合标准铂类双药化疗已被证明可改善晚期 NSCLC 患者的结局。几种多靶点抗血管生成酪氨酸激酶抑制剂（如索拉非尼、舒尼替尼、西地尼布、凡德他尼、BIBF 1120、帕唑帕尼和阿昔替尼）也正在与标准化疗联合进行评估。在此，我们回顾了晚期 NSCLC 患者中抗血管生成药物联合细胞毒性化疗的现有临床数据。
相似文献
1
Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.
Cancer Invest. 2011 May;29(4):325-37. doi: 10.3109/07357907.2011.554476.
2
Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials.
Eur J Clin Pharmacol. 2013 Feb;69(2):151-9. doi: 10.1007/s00228-012-1333-3. Epub 2012 Jun 24.
3
Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?
Cancer Biol Ther. 2012 Mar;13(5):247-63. doi: 10.4161/cbt.19594.
4
Antiangiogenic therapies in non-small-cell lung cancer.
Curr Oncol. 2018 Jun;25(Suppl 1):S45-S58. doi: 10.3747/co.25.3747. Epub 2018 Jun 13.
5
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Curr Treat Options Oncol. 2007 Feb;8(1):15-27. doi: 10.1007/s11864-007-0022-4.
6
Bevacizumab in non-small cell lung cancer.
Drugs. 2008;68(6):737-46. doi: 10.2165/00003495-200868060-00002.
7
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Clin Lung Cancer. 2009 Mar;10 Suppl 1(Suppl 1):S7-16. doi: 10.3816/CLC.2009.s.002.
8
Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.
Oncologist. 2008;13 Suppl 1:5-13. doi: 10.1634/theoncologist.13-S1-5.
9
Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC).
Target Oncol. 2013 Mar;8(1):15-26. doi: 10.1007/s11523-013-0261-1. Epub 2013 Feb 1.
10
New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Clin Lung Cancer. 2008;9 Suppl 3:S100-8. doi: 10.3816/CLC.2008.s.015.
引用本文的文献
1
Identification of Key Biomarkers and Candidate Molecules in Non-Small-Cell Lung Cancer by Integrated Bioinformatics Analysis.
Genet Res (Camb). 2023 Jan 3;2023:6782732. doi: 10.1155/2023/6782732. eCollection 2023.
2
Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer.
Bioorg Med Chem. 2021 Apr 1;35:116061. doi: 10.1016/j.bmc.2021.116061. Epub 2021 Feb 12.
3
Identification of novel biomarkers and candidate small molecule drugs in non-small-cell lung cancer by integrated microarray analysis.
Onco Targets Ther. 2019 May 13;12:3545-3563. doi: 10.2147/OTT.S198621. eCollection 2019.
4
VEGFR-TKIs combined with chemotherapy for advanced non-small cell lung cancer: A systematic review.
J Cancer. 2019 Jan 30;10(4):799-809. doi: 10.7150/jca.29643. eCollection 2019.
5
The expression level and prognostic value of HIPK3 among non-small-cell lung cancer patients in China.
Onco Targets Ther. 2018 Oct 25;11:7459-7469. doi: 10.2147/OTT.S166878. eCollection 2018.
6
Upregulation of the Long Noncoding RNA SNHG3 Promotes Lung Adenocarcinoma Proliferation.
Dis Markers. 2018 Jul 22;2018:5736716. doi: 10.1155/2018/5736716. eCollection 2018.
7
Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response.
J Gastrointest Cancer. 2019 Dec;50(4):943-946. doi: 10.1007/s12029-018-0130-3.
8
Evaluation of efficacy and safety for bevacizumab in treating malignant pleural effusions caused by lung cancer through intrapleural injection.
Oncotarget. 2017 Dec 6;8(69):113318-113330. doi: 10.18632/oncotarget.22966. eCollection 2017 Dec 26.
9
Effects of silencing Rab27a gene on biological characteristics and chemosensitivity of non-small cell lung cancer.
Oncotarget. 2017 Oct 10;8(55):94481-94492. doi: 10.18632/oncotarget.21782. eCollection 2017 Nov 7.
10
DISC1 overexpression promotes non-small cell lung cancer cell proliferation.
Oncotarget. 2017 May 22;8(39):65199-65210. doi: 10.18632/oncotarget.18055. eCollection 2017 Sep 12.
本文引用的文献
1
Phase II Trial of Dose-dense Pemetrexed, Gemcitabine, and Bevacizumab in Patients With Advanced, Non-Small-cell Lung Cancer.
Clin Lung Cancer. 2017 May;18(3):299-302. doi: 10.1016/j.cllc.2016.11.019. Epub 2016 Dec 2.
2
Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies.
Oncologist. 2013;18(3):273-80. doi: 10.1634/theoncologist.2012-0339. Epub 2013 Mar 13.
3
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours.
Br J Cancer. 2012 Oct 9;107(8):1277-85. doi: 10.1038/bjc.2012.406. Epub 2012 Sep 18.
4
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.
J Clin Oncol. 2011 Mar 10;29(8):1067-74. doi: 10.1200/JCO.2010.29.5717. Epub 2011 Jan 31.
5
A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer.
J Thorac Oncol. 2010 Nov;5(11):1821-5. doi: 10.1097/JTO.0b013e3181f1d23c.
6
Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.
Lancet Oncol. 2010 Aug;11(8):733-40. doi: 10.1016/S1470-2045(10)70151-0. Epub 2010 Jul 23.
7
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
Lancet Oncol. 2010 Jul;11(7):619-26. doi: 10.1016/S1470-2045(10)70132-7.
8
Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.
J Clin Oncol. 2010 Jul 1;28(19):3131-7. doi: 10.1200/JCO.2009.23.9749. Epub 2010 Jun 1.
9
Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients.
Clin Cancer Res. 2010 May 15;16(10):2881-9. doi: 10.1158/1078-0432.CCR-09-2944. Epub 2010 May 11.
10
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
J Clin Oncol. 2010 May 1;28(13):2137-43. doi: 10.1200/JCO.2009.26.5561. Epub 2010 Apr 5.
Zotero 插件